Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. •• Turner D et al., “STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD,” Gastroenterology, 2021/02/19/ 2021, doi: 10.1053/j.gastro.2020.12.031. An evidence-based international expert consensus recommendations from the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) for treat-to-target strategies in adults and children with IBD.
2. •• Le Berre C et al., “Selecting endpoints for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD,” Gastroenterology, 2021/01/06/ 2021, doi: 10.1053/j.gastro.2020.10.065. An evidence-based international expert consensus recommendations from the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) for the selection of endpoints to be used in future IBD-disease modification trials.
3. Ungaro R, Colombel JF, Lissoos T, and Peyrin-Biroulet L, “A treat-to-target update in ulcerative colitis: a systematic review,” (in eng), Am J Gastroenterol, vol. 114, no. 6, pp. 874-883, Jun 2019, doi: 10.14309/ajg.0000000000000183.
4. Abreu MT and Sandborn WJ, “Defining endpoints and biomarkers in inflammatory bowel disease: moving the needle through clinical trial design,” (in eng), Gastroenterology, vol. 159, no. 6, pp. 2013-2018.e7, Dec 2020, doi: 10.1053/j.gastro.2020.07.064.
5. B. E. Sands et al., “The impact of raising the bar for clinical trials in ulcerative colitis,” (in eng), J Crohns Colitis, vol. 13, no. 9, pp. 1217-1226, Sep 19 2019, doi: 10.1093/ecco-jcc/jjz038.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献